Both Fish Oil and Olive Oil Lowered Plasma Fibrinogen in Women with High Baseline Fibrinogen Levels

Summary

This double-blind, cross-over study with olive oil as placebo, examined the effect of a daily dosage of 6 g fish oil on cardiovascular risk markers of 20 healthy young volunteers (10 men, 10 women). Serum lipids and lipoproteins, and plasma coagulation and fibrinolytic enzymes, including fibrinogen concentrations and plasminogen activator inhibitor-1 (PAI-1) activity were measured at baseline and after 6-week supplementation of either fish or olive oil. The results showed that fish oil had an independent lowering effect on triglycerides and coagulation factors Vc and VIIc. Both fish and olive oil significantly raised PAI-1 levels and lowered plasma factor Xc and fibrinogen levels in the women, who had higher initial levels than the men. Mean fibrinogen levels of the women were lowered from 3.23 ± 0.98 to 2.64 ± 0.55 g/1 and from 3.19 ± 0.72 to 2.66 ± 0.49 g/1 by fish and olive oil respectively. This study raises the question whether a particular fatty acid or group of fatty acids, or another constituent of the oil such as vitamin E may be responsible for the fibrinogen lowering effect.

• References

• Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; 2: 433-435
• 2 Hirai A, Hamazaki T, Terano T, Nishikawa T, Tamura Y, Kumagai A. Eicosapentaenoic acid and platelet function in Japanese. Lancet 1980; 2: 1132-1133
• 3 Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-807
• 4 Von Schacky C, Fisher S, Weber PC. Long-term effects of dietary marine ω-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 1985; 76: 1626-1631
• 5 Terano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamura Y, Kumagai A. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331
• 6 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular diseae: The Framingham Study. JAMA 1987; 258: 1183-1186
• 7 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 8 Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. TIPS 1990; 11: 444-451
• 9 Flaten H, Høstmark AT, Kierulf P, Lystad E, Trygg K, Bjerkedal T, Osland A. Fish-oil concentrate: effects on variables related to cardiovascular disease. Am J Clin Nutr 1990; 52: 300-306
• 10 Høstmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 180-181
• 11 Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: A randomized, double-blind controlled study. Ann Intern Med 1989; 111: 757-758
• 12 Radack K, Deck C, Huster G. The comparative effects of n-3 and n-6 polyunsaturated fatty acids on plasma fibrinogen levels: A controlled clinical trial in hypertriglyceridemic subjects. J Am Coll Nutr 1990; 9: 352-357
• 13 Saynor R, Gillott T. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 1196
• 14 Brown AJ, Roberts DCK. Fish and fish oil intake: effect on haematological variables related to cardiovascular disease. Thromb Res 1991; 64: 169-178
• 15 Emeis JJ, Van Houwelingen AC, Van Den Hoogen CM, Homstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. Blood 1989; 74: 233-237
• 16 Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990; 227: 347-353
• 17 Hendra TJ, Britton ME, Roper DR, Wagaine-Twabwe D, Jeremy JY, Dandona P, Haines AP, Yudkin JS. Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care 1990; 13: 821-829
• 18 Lox CD. The effect of dietary marine fish oils (omega-3 fatty acids) on coagulation profiles in men. Gen Pharmac 1990; 21: 241-246
• 19 Muller AD, Van Houwelingen AC, Van Dam-Mieras MCE, Bas BM, Horn-stra G. Effects of a moderate fish intake on haemostatic parameters in healthy males. Thromb Haemost 1989; 61: 468-473
• 20 Norris PG, Jones CJH, Weston MJ. Effect of dietary supplementation with fish oil on systolic blood pressure in mild essential hypertension. Br Med J 1986; 293: 104-105
• 21 Rogers S, James KS, Butland BK, Etherington MD, O’Brien JR, Jones JG. Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, haemostatic and rheological variables. Atherosclerosis 1987; 63: 137-143
• 22 Haines AP, Sanders TAB, Imeson JD, Mahler RF, Martin J, Mistry M, Vickers M, Wallace PG. Effects of a fish oil supplement on platelet function, haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb Res 1986; 43: 643-655
• 23 Silvis N, Vorster HH, Mollentze WF, De Jager J, Huisman HW. Metabolic and haemostatic consequences of dietary fibre and n-3 fatty acids in black type 2 (NIDDM) diabetic subjects: A placebo controlled study. Intern Clin Nutr Rev 1990; 10: 362-380
• 24 Smith P, Amesen H, Opstad T, Dahl KH, Eritsland J. Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulant or matching placebo. Thromb Res 1989; 53: 467-474
• 25 Schmidt EB, Lervang HH, Vanning K, Madsen P, Dyerberg J. Long-term supplementation with n-3 fatty acids, I: Effect on blood lipids, haemostasis and blood pressure. Scand J Clin Lab Invest 1992; 52: 221-228
• 26 Benade AJS, Fincham JE, Smuts CM, Lai Tung MT, Chalton D, Kruger M, Weight MJ, Daubitzer AK, Tichelaar HY. 1988. Plasma low density lipoprotein composition in relation to atheroclerosis in nutritionally defined Vervet monkeys. Atherosclerosis 1988; 74: 157-168
• 27 Langenhoven ML, Conradie PJ, Wolmarans P, Faber M. MRC Food quantities manual. 2nd edition. Medical Research Council, Cape Town, South Africa 1991; 89
• 28 Gouws E, Langenhoven ML. Fatty acid composition. Amino acid composition. First supplement to NRIND Food Composition Tables. 2nd edition. Medical Research Council, Cape Town, South Africa 1986: 80
• 29 Macleod J. Davidson’s principles and practice of medicine. 12th edition. Edinburgh: Churchill Livingstone 1978; 978
• 30 Donahue RP, Orchard TJ, Becker PJ, Kuller LH, Drash AL. Physical activity, insulin sensitivity, and the lipoprotein profile in young adults: the Beaver County Study. Am J Epidemiol 1988; 127: 95-103
• 31 Mahan LK, Arlin M. Carbohydrates. In: Krause’s food, nutrition and diet therapy Philadelphia: Saunders: 1992: 36
• 32 Rossouw JE, Steyn K, Berger GMB, Vermaak WJH, Kock J, Seftel HC, Gevers W. Action limits for serum total cholesterol. A statement for the medical profession by an ad hoc committee of the Heart Foundation of South Africa. SA Med J 1988; 73: 693-700
• 33 Venter CS, Vorster HH, Silvis N, Kruger A, Mia F, Seftel HC. Determinants of plasma fibrinogen levels in South African Communities. In: Fibrinogen: a “new”cardiovascular risk factor Ernst E, Koenig W, Lowe GDO, Meade TW. (eds). Blackwell-MZV, Vienna, Austria: 1992: 166-171
• 34 Assmann G, Schulte H. Results and conclusions of the prospective cardiovascular Munster (PROCAM) study. In: Lipid metabolism disorders and coronary heart disease Primary prevention, diagnosis and therapy guidelines for general practice. Assmann G. (ed). Munchen, MMV Medizin Verlag: 1993: 24-67
• 35 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
• 36 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Cin Epidemiol 1990; 43: 913-919
• 37 Ernst E. Oral contraceptives, fibrinogen and cardiovascular risk. Atherosclerosis 1991; 93: 1-5
• 38 Blonk MC, Bilo HJC, Nauta JJP, Popp-Snijders C, Mulder C, Donker AJM. Dose-response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr 1990; 52: 120-127
• 39 Deck C, Radack K. Effects of modest doses of omega-3 fatty acids on lipids and lipoproteins in hypertriglyceridemic subjects. A randomized controlled trial. Arch Intern Med 1989; 149: 1857-1862
• 40 Nikkilä M. Influence of fish oil on blood lipids in coronary artery disease. Eur J Clin Nutr 1991; 45: 209-213
• 41 Delany JP, Vivian VM, Snook JT, Anderson PA. Effects of fish oil on serum lipids in men during a controlled feeding trial. Am J Clin Nutr 1990; 52: 477-485
• 42 Asplund-Carlson A, Hamsten A, Wiman W, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825
• 43 Siegert G, Bergmann S, Jaross W. Influence of age, gender and lipoprotein metabolism parameters on the activity of plasminogen activator and the fibrinogen concentration. Fibrinolysis 1992; 6: 47-51
• 44 Raccah D, Alessi MC, Seelies V, Menard C, Juhan-Vague I, Vague P. Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. Fibrinolysis 1993; 7: 171-176
• 45 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and athero-thrombosis. Diabetologia 1991; 34: 457-462
• 46 Kluft C, Potter Van Loon BJ, De Maat MPM. Insulin resistance and changes in haemostatic variables. Fibrinolysis 1992; 6: 11-16
• 47 Barcelli U, Glas-Greenwalt P, Poliak VE. Enhancing effect of dietary supplementation with ω-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 1985; 39: 307-312
• 48 Mehta J, Lawson D, Saldeen T. Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. Am Heart J 1988; 116: 1201-1206
• 49 Fumeron F, Brigant L, Ollivier V, De Prost D, Driss F, Darcet P, Bard J, Parra H, Fruchart J, Apfelbaum M. n-3 polyunsaturated fatty acids raise low-density lipoproteins, high-density lipoprotein 2, and plasminogen-ac-tivator inhibitor in healthy young men. Am J Clin Nutr 1991; 54: 118-122
• 50 Fröschl H, Spannagl M, Drummer C, Landgraf-Leurs MMC, Landgraf R, Schramm W. Effect of eicosapentaenoic acid diet on humoral clotting and fibrinolysis parameters in type 1 diabetes mellitus. Haemostasis 1988; 18: 27-28
• 51 Nilsson TK, Hellsten G, Kallmans G, Boman K. Effects of cod liver oil and com oil on the fibrinolytic system: A randomised double-blind trial. International journal of fibrinolysis, thrombolysis, and extracellular proteolysis 1992; 6: 141
• 52 Moller JM, Svaneborg N, Lervang HH, Varming K, Madsen P, Dyerberg J, Schmidt EB. The acute effect of a single dose of n-3 fatty acids on coagulation and fibrinolysis. Thromb Res 1992; 67: 569-577
• 53 Iacoviello L, Amore C, De Curtis A, Tacconi MT, De Gaetano G, Cerletti C, Donati MB. Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids. Arterioscler Thromb 1992; 12: 1191-1197
• 54 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and athero-thrombosis. Thromb Haemost 1993; 70: 138-143
• 55 Haglund O, Luostarinen R, Wallin R, Wibell L, Saldeen T. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. Lipids 1991; 121: 165-169